Browsing Clinical Studies by author "Khoo, Vincent"
Now showing items 1-2 of 2
-
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley, D; Syndikus, I; Mossop, H; Khoo, V; Birtle, A; Bloomfield, D; Graham, J; Kirkbride, P; Logue, J; Malik, Z; Money-Kyrle, J; O'Sullivan, JM; Panades, M; Parker, C; Patterson, H; Scrase, C; Staffurth, J; Stockdale, A; Tremlett, J; Bidmead, M; Mayles, H; Naismith, O; South, C; Gao, A; Cruickshank, C; Hassan, S; Pugh, J; Griffin, C; Hall, E; CHHiP Investigators (2016-08)<h4>Background</h4>Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects ... -
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins, A; Mossop, H; Syndikus, I; Khoo, V; Bloomfield, D; Parker, C; Logue, J; Scrase, C; Patterson, H; Birtle, A; Staffurth, J; Malik, Z; Panades, M; Eswar, C; Graham, J; Russell, M; Kirkbride, P; O'Sullivan, JM; Gao, A; Cruickshank, C; Griffin, C; Dearnaley, D; Hall, E (2015-12)<h4>Background</h4>Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after ...